Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yogen Saunthararajah

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2013
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesYogen Saunthararajah
Haematologica|October 15, 2020
Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiationYogen Saunthararajah
Pediatric Hematology and Oncology|September 6, 2007
Decitabine and sickle cell disease: molecular therapy for a molecular diseaseYogen Saunthararajah
Haematologica|August 11, 2019
Targeting sickle cell disease root-cause pathophysiology with small moleculesYogen Saunthararajah
Blood|March 25, 2021
β-Hemoglobinopathies lead the wayYogen Saunthararajah
Blood|May 16, 2015
Targets of opportunity for precision medicineYogen Saunthararajah
The Journal of Clinical Investigation|April 15, 2024
Oncotherapy resistance explained by Darwinian and Lamarckian modelsYogen Saunthararajah
British Journal of Haematology|March 1, 2020
Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixationXiaorong Gu, Yogen Saunthararajah
Blood|March 3, 2012
CEBPE activation in PML-RARA cells by arsenicZhenbo Hu, Yogen Saunthararajah
Seminars in Hematology|November 10, 2004
Clinical studies with fetal hemoglobin-enhancing agents in sickle cell diseaseYogen Saunthararajah, Joseph DeSimone
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Hematology. American Society of Hematology. Education Program|December 10, 2013
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesYogen Saunthararajah
Haematologica|October 15, 2020
Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiationYogen Saunthararajah
Pediatric Hematology and Oncology|September 6, 2007
Decitabine and sickle cell disease: molecular therapy for a molecular diseaseYogen Saunthararajah
Haematologica|August 11, 2019
Targeting sickle cell disease root-cause pathophysiology with small moleculesYogen Saunthararajah
Blood|March 25, 2021
β-Hemoglobinopathies lead the wayYogen Saunthararajah
Blood|May 16, 2015
Targets of opportunity for precision medicineYogen Saunthararajah
The Journal of Clinical Investigation|April 15, 2024
Oncotherapy resistance explained by Darwinian and Lamarckian modelsYogen Saunthararajah
British Journal of Haematology|March 1, 2020
Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixationXiaorong Gu, Yogen Saunthararajah
Blood|March 3, 2012
CEBPE activation in PML-RARA cells by arsenicZhenbo Hu, Yogen Saunthararajah
Seminars in Hematology|November 10, 2004
Clinical studies with fetal hemoglobin-enhancing agents in sickle cell diseaseYogen Saunthararajah, Joseph DeSimone
Pageof 15